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Abstract The purpose of this study was to determine the
pattern and extent of caudate nucleus and putamen atrophy
in HIV-infected men with well-controlled immune status
and viral replication. 155 men underwent structural brain
magnetic resonance imaging; 84 were HIV-infected and 71
were uninfected controls. MRI data were processed using
the Fully Deformable Segmentation routine, producing
volumes for the right and left caudate nucleus and putamen,
and 3-D maps of spatial patterns of thickness. There was
significant atrophy in the HIV-infected men in both the
caudate and putamen, principally in the anterior regions.
The volume of the basal ganglia was inversely associated
with the time since first seropositivity, suggesting that
either there is a chronic, subclinical process that continues
in spite of therapy, or that the extent of the initial insult
caused the extent of atrophy.
Keywords HIV.MRI.Gray matter.Basal ganglia
The statistical analyses were completed by J. Becker, J. Sanders, S.
Madsen, L. Kingsley. P. Saharan, and V. Maruca.
J. Sanders was formerly J. Mullen.
The Multicenter AIDS Cohort Study (MACS) includes the following
investigators: Baltimore: The Johns Hopkins University Bloomberg
School of Public Health: Joseph B. Margolick (Principal Investigator),
Haroutune Armenian, Barbara Crain, Adrian Dobs, Homayoon
Farzadegan, Joel Gallant, John Hylton, Lisette Johnson, Shenghan
Lai, Ned Sacktor, Ola Selnes, James Shepard, Chloe Thio. Chicago:
Howard Brown Health Center, Feinberg School of Medicine,
Northwestern University, and Cook County Bureau of Health
Services: John P. Phair (Principal Investigator), Joan S. Chmiel (Co-
Principal Investigator), Sheila Badri, Bruce Cohen, Craig Conover,
Maurice O’Gorman, David Ostrow, Frank Palella, Daina Variakojis,
Steven M. Wolinsky. Los Angeles: University of California, UCLA
Schools of Public Health and Medicine: Roger Detels (Principal
Investigator), Barbara R. Visscher (Co-Principal Investigator), Aaron
Aronow, Robert Bolan, Elizabeth Breen, Anthony Butch, Thomas
Coates, Rita Effros, John Fahey, Karl Goodkin, Beth Jamieson,
Otoniel Martínez-Maza, Eric N. Miller, John Oishi, Paul Satz, Harry
Vinters, Dorothy Wiley, Mallory Witt, Otto Yang, Stephen Young,
Zuo Feng Zhang. Pittsburgh: University of Pittsburgh, Graduate
School of Public Health: Charles R. Rinaldo (Principal Investigator),
Lawrence A. Kingsley (Co-Principal Investigator), James T. Becker,
Ross D. Cranston, Jeremy J. Martinson, John W. Mellors, Anthony J.
Silvestre, Ronald D. Stall. Data Coordinating Center: The Johns
Hopkins University Bloomberg School of Public Health: Lisa P.
Jacobson (Principal Investigator), Alvaro Munoz (Co-Principal
Investigator), Stephen R. Cole, Christopher Cox, Gypsyanber
D’Souza, Stephen J. Gange, Janet Schollenberger, Eric C. Seaberg,
Sol Su. NIH: National Institute of Allergy and Infectious Diseases:
Robin E. Huebner; National Cancer Institute: Geraldina Dominguez;
National Heart, Lung and Blood Institute: Cheryl McDonald; National
Institute of Mental Health: Pim Brouwers.
Electronic supplementary material The online version of this article
(doi:10.1007/s11682-011-9113-8) contains supplementary material,
which is available to authorized users.
J. T. Becker
University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA
J. Sanders
Bloomberg School of Public Health,
Baltimore, MD, USA
S. K. Madsen: P. Saharan: P. M. Thompson
Laboratory of NeuroImaging, UCLA School of Medicine,
Los Angeles, CA, USA
A. Ragin:B. Cohen
Feinberg School of Medicine, Northwestern University,
Chicago, IL, USA
L. Kingsley





Brain Imaging and Behavior (2011) 5:77–85
DOI 10.1007/s11682-011-9113-8Introduction
Changes in the structure of the central nervous system have
been consistently reported in HIV disease, with the caudate
nucleus (CDT) and putamen (PUT) particularly vulnerable,
especially in severely immunosuppressed patients (Berger and
Arendt 2000; Berger and Nath 1997; Stout et al. 1998). These
brain changes are in turn associated with substantial cognitive
impairments that form a major public health problem related
to HIV (Dal Pan et al. 1992;H e s t a de ta l .1993;K i e b u r t ze t
al. 1996; Levin et al. 1990; Moeller and Backmund 1990).
The development of highly active antiretroviral therapies
(HAART) led to the hope that regulation of immune status
and viral replication may help to ameliorate HIV-associated
subcortical brain changes and subsequent cognitive impair-
ment, but data supporting this conjecture are mixed. For
example, one study reported a hypertrophy of the PUT of
HIV-infected individuals with mild cognitive dysfunction,
with increased putamen volume related to decreased motor
speed (Castelo et al. 2007). Another recent study (Paul et al.
2008) found similar associations but in the opposite
direction, and the putamen was (on average) smaller in
the HIV-infected individuals.
The aim of this study was to evaluate HIV-associated
changes in the CDTand PUT, in a sample of older men (N=
155; age >50 years) recruited from the Multicenter AIDS
Cohort Study (MACS). This investigation exploited sensi-
tive new Magnetic Resonance (MR) image analysis
algorithms to derive in vivo measurements of basal ganglia
volumes and the spatial distribution of atrophy (Chiang et
al. 2007). We assessed the effects of HIV on the presence,
location, and extent of basal ganglia atrophy in the HIV +
group versus controls, and evaluated how these global and
local volume reductions relate to specific clinical features,
including immunological and virological status.
Methods
This study was approved by the ethical standards committee
on human experimentation at each of the MACS sites.
Written informed consent was obtained from all participants.
Participants
160 men were enrolled from the Cardiovascular Substudy
of the MACS (Kingsley et al. 2008) and scanned between
2008 and 2009. Of the MRI data that were sent to
Pittsburgh for processing, scans from 4 could not be
adequately processed to obtain the mesh images; one
additional participant could not tolerate the MR environ-
ment and was dropped from the study. Therefore, data from
155 participants are reported here (84 HIV+, 71 HIV-).
There were small group differences in age and education
(r’s ~ .18), but none in the measures of drug use or in the
racial distribution of the participants (See Table 1). Thirty-
one percent of the HIV-infected men had detectable viral
load, and 8% were immunosuppressed. Sixty-five of the
infected men had viral loads and CD4+ cell counts
available prior to the initiation of HAART. Viral loads
and CD4+ counts were derived from biological specimens
collected during MACS visits. The mean peak viral load in
these infected men (N=65) was >4.5 log units (range: 1.6–
6.3), and the mean CD4+ nadir was less than 230 (range:
15–713). We identified the date of earliest known seropos-
itivity; for 19 of the 84 HIV-infected men (23%), we were
able to impute a date between the last known MACS visit
seen seronegative and the first known MACS visit seen
positive (i.e., incident infection). The remaining 65 partic-
ipants were infected when they joined the MACS (i.e.,
prevalent infection), so their earliest known date of
infection was set to their date of enrollment.
Magnetic resonance imaging
The anatomical imaging sequence was developed by the
Alzheimer’s Disease Neuroimaging Initiative for use with
3T scanners (http://www.adni-info.org/images/stories//
mritrainingmanualv1.pdf). Three of the sites used Siemens
3 T Trio scanners (maximum gradient slew rate: 200 mT/m/s;
maximum gradient strength 40 mT/m), with the Siemens
phase-array head coil. One of the sites (Los Angeles) used a
Siemens Allegra scanner. The sagittal Magnetization Prepared
Rapid Acquisition Gradient Echo (MP-RAGE) sequence was:
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We used the Fully Deformable Segmentation (Carmichael
et al. 2007a, b) routine, first stripping the skull, scalp, and
extraneous tissue from the brain using a recursive form of
the Brain Extraction Tool (Fagiolo et al. 2008). Once the
brain was extracted, a high-resolution single-subject aver-
age MRI scan (Holmes et al. 1998) was normalized to the
subject space using a fully-deformable registration method
(Chen 1999). The deformation parameters from this step are
used to align the template masks of the CDT and PUT to
the subject brain. Because the globus pallidus was difficult
to identify reliably, we did not include this structure in the
analysis. The aligned masks were used to extract the
volume of the ROIs, and to generate surface maps. This
method has been validated against manually derived data in
patients with HIV disease (Carmichael et al. 2007a, b).
Anatomical mesh modeling methods were then used to
match equivalent CDT and PUT surface points obtained
from the automated tracings, across participants and
groups (Thompson et al. 2004). The surface contours were
made uniform by modeling them as a 3-D parametric
surface mesh (Thompson et al. 1996) allowing measure-
ments to be made at corresponding surface locations in each
participant. This procedure also allows the averaging of
CDT and PUT surface morphology across all individuals
belonging to a group and records the amount of variation
between corresponding surface points relative to the group
averages.
To assess global atrophy of the CDT and PUT, the
volume of each structure, measured as part of the tissue
segmentation routine, was expressed as a percent of the
total brain volume (see Table 2). We created a single
summary variable to reflect the total volume of these two
basal ganglia subregions by summing the four individual
values, and dichotomized their total volume based on the
median of all 155 participants. To measure local atrophy, a
3-D curve was derived from each individual CDT and PUT
surface mesh down their central axis. The distance of each
surface point from this centerline measures the radial size of
the individual structures, and statistical maps were gener-
ated showing local group differences. Regression analyses
were run at each surface point to map linkages with radial
size, and the local p value was plotted onto the surface at
each point. Overall corrected p values were also assigned to
the maps using permutation testing to give an overall
HIV − HIV + (r, p )
N = 71 84
Age 57.9 (6.3) 55.8 (4.9) −.18, .02
Education 16.4 (2.55) 15.04 (2.6) −.17, .04
Race (%(N) white) 82 (58) 74 (62) .09, >.20
Handedness (%(N) right-handed) 87 (59) 87 (71) .01, >.20
Crack cocaine
a 16 (11) 24 (20) .10, .20
Cocaine
a 7 (12) 27 (23) .13, .12
Uppers
a,b 7 (5) 17 (14) .15, .07
CESD ≥ 16 (N(%))
a 18 (13) 17 (14) −.02, .79
Diabetes
a,c 17 (12) 12 (10) −.07, .23
High blood pressure
a,c 42 (30) 43 (36) .01, .82
CD4+ <200 (N(%))
1 n/a 8 (6) –
Current detectable viral load (N(%))
a n/a 31 (24) –
CD4+ current n/a 540 (270) –
CD4+ nadir n/a 222 (135) –
HIV RNA current
d n/a 3.22 (1.1) –
HIV RNA peak n/a 4.60 (1.2) –
HAART use (N(%)) n/a 71 (88) –
CDT volume 1.24 (.14) 1.12 (.16) −.39, <.001
Left .69 (.08) .61 (.10) −.40, <.001
Right .54 (.07) .49 (.07) −.32, <.001
PUT volume 1.05 (.20) .89 (.16) −.39, <.001
Left .67 (.12) .57 (.11) −.39, <.001
Right .38 (.09) .32 (.06) −.35, <.001
Basal ganglia summary 2.29 (.32) 2.02 (.31) −.41, <.001
Table 1 Characteristics of
study participants
aPercent (N)
bDefined as “speed, meth
or ice”
cDefined as self-report, told
by physician, or taking
pharmacotherapy
bAmong men with detectable
virus
Brain Imaging and Behavior (2011) 5:77–85 79significance value for the effect, adjusting for multiple
comparisons (Lin et al. 2005; Thompson et al. 2004)
Results
The volumes of the CDT and PUT, adjusted for total brain
volume ((region/total)*100), were significantly smaller in
the HIV-infected men than in the controls (see Table 1).
Table 2 shows the unadjusted risks of having a smaller total
basal ganglia volume (i.e., below the median of all 155
subjects) as a function of a range of participant character-
istics. Only HIV serostatus was significantly linked to the
size of the basal ganglia overall; none of the other between-
group differences were significant.
We then examined the relationship between HIV-
associated factors and the summary volume. For these
analyses the basal ganglia summary variable was dichoto-
mized at the median of the HIV-infected participants only.
The data were divided based on the group median because
we were interested in examining the factors associated with
atrophy in the HIV-infected men. We found no significant
differences between the two groups of infected men in
terms of their current CD4+ cell count or HIV viral load, or
the nadir CD4+ cell count and peak HIV viral load (see
Table 3). There was no effect of using antiretroviral
medications with greater CNS penetrance on basal ganglia
volume (Letendre et al. 2008). We did find a significant
difference in the number of years of infection, such that here
was a trend for the time since seroconversion (i.e., n=19) to
be longer among the men with smaller basal ganglia; the
effect size did not differ from that of the men with prevalent
infection (i.e., r=.39 vs. r=.45) (See Supplementary
Figure E-1). We regressed the basal ganglia summary
volume on age, race, and time since first known seroposi-
tivity in all 84 HIV-infected men. Only the time variable was
related to volume (β=−.48, t(83) = 4.20, p<.001), and
neither age (β=−.11, p>.10) nor race (β=−.12, p>.10)were
associated with basal ganglia volume. When we compared
the HIV-infected men as a function of the time since first
seropositivity (Table 4), only the summary basal ganglia
volume and age differed among the groups (See also
Supplemental Figure E-2).
Figure 1 shows the regions of the CDT and PUT where
the mean radial size of these structures was lower in the
HIV-infected than in the control group (See also Supple-
mental Figure E-3). The level of local atrophy was
significantly associated with serostatus (all corrected p
values, computed by permutation testing were less than
0.001, see Supplemental Table E-1). There were no regions
of local expansion that reached statistical significance for
either the caudate or the putamen.
Among the HIV-infected men, we found a significant
effect of time since first confirmed seropositivity (as above)
and local shape differences (See Supplemental Table E-1).
The spatial distribution of the atrophy is not uniform, with
CDT atrophy primarily in the anterior regions, whereas the
PUT atrophy is more evenly distributed. The pattern of
local atrophy as a function of time since seropositivity
resembles that of the HIV effect, but to a lesser extent.
Factors Total basal ganglia volume
Above median Below median Statistics
c
N= 77 78
Group (HIV +) 34 (26) 58 (74) 25.7, 5.69, <.001
Race (Non-White) 27 (21) 18 (14) 1.93, .58, .12
Crack use
a 20 (15) 21 (16) .03, 1.07, >.10
Other cocaine
a 21 (16) 24 (19) .28, 1.23, >.10
Uppers
a 10 (8) 14 (11) .50, 1.42, >.10
Diabetes 13 (10) 15 (12) .183, 1.21, >.10
Depression
b 17 (13) 18 (14) .03, 1.08, >.10
Age 57.4 (6.1) 56.7 (4.5) .78, −.06, >.10
Education 16.2 (2.7) 16.1 (2.5) .13, −.01, >.10
Systolic BP 129.0 (14.8) 128.5 (15.1) .22, −.02, >.10
Diastolic BP 78.1 (10.0) 77.1 (9.4) .56 (−.05), >.10
Fasting glucose 103.4 (15.8) 107.8 (60) −.57, .05, >.10
Hemoglobin A1C 57.0 (10.8) 56.9 (14.7) .50, −.04, >.10
Total cholesterol 188.1 (33) 200.2 (58) −1.60, .13, .11
HDL 504.8 (134) 494.4 (171) .42, −.03, >.10
LDL 106.5 (30) 111.7 (36) −.97, .08, >.10
Table 2 Factors associated
with basal ganglia volume
(percent (N))
aAny use in the last 5 years
bCES-D score >16
c#
2, Odds Ratio and p for
dichotomous variables; t, r and
p for continuous variables
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The results of this study show that in the era of HAART,
among HIV-infected individuals with access to medical care,
thereisstillmeasurableatrophyinsubcorticalbrainstructures.
We present here for the first time, selective patterns of atrophy
in the 3-D surface contours of the CDTand PUTas a function
of HIV disease. We have previously found alterations in the
basal ganglia using tensor-based analyses (Chiang et al. 2007;
Lepore et al. 2008), but this is the first description of the
local contractions in the shape of these structures. Further-
more, we have linked the location of the atrophy to the time
since first seropositivity. Thus, at both a global and local
level, we found that basal ganglia volume remains exqui-
sitely sensitive to the presence of the HIV virus. Further-
more, the longer an individual is infected with HIV, the
greater the loss in volume. The explanation for these findings
cannot be conclusively determined in this cross-sectional
study, but there are at least two general hypotheses that offer
important clues for our understanding of the epidemic.
First, the “time” variable reflects both incident infection
(i.e., with a better estimate of date of infection) and
prevalent infection (where the infection occurred at some
time prior to enrollment in the MACS). The most
parsimonious explanation of the time effect is that it is
related to the enrollment of new recruits into the MACS.
Volunteers entered in three waves: 1984/85, 1987/90, and
in 2001/03 (primarily from racial/ethnic minorities); the
men joining in 2001–2003 were generally already infected.
The majority of our seropositive volunteers (57%) were
either infected at the time of enrollment 25 years ago, or
were infected soon thereafter. A smaller group became
infected in the following 10 years of the study, and the
remainder (27%) either entered the study with HIV
Basal ganglia volumes
Above median Below median (t, r, p)
N4 2 4 2
CD4 cell counts
Current 515.7 (278) 566.3 (262) −.82, .09, >.10
Nadir
a 213.4 (138) 238.5 (114) −.80, .10, >.10
HIV viral load
Current 1.94 (.79) 2.18 (1.06) −1.17, .13, >.10
Peak
b 5.03 (.56) 4.92 (.66) .68, −.09, >.10
Years since first positive visit
c 13.1 (8.6) 20.3 (5.6) 4.53, .45, <.001
Years since seroconversion (n =19) 12.0 (6.8) 16.8 (4.8) 1.74, .39, .10
Use of HAART (Percent (N)) 83 (35) 74 (31) 1.20, −.12, .55
d
Rank of HAART CNS penetrance 1.71 (.76) 1.63 (.66) 0.473, .003, .648
Table 3 Factors associated with
HIV disease and basal ganglia
volumes
aLowest measured CD4+ cell
count prior to HAART (n=65)
bHighest HIV RNA prior to
HAART (n=65)
cVisit with first confirmed HIV
seropositivity. Includes both




Table 4 Participant characteristics as a function of duration of infection
Less than 10 years 10–20 years Greater than 20 years (F,r ,p )
N2 3 1 3 4 8
Time since infection
a 4.26 (.86) 16.2 (2.7) 22.7 (.57) 1787, .99, <.001
Basal ganglia volume 2.25 (.31) 2.00 (.28) 1.91 (.25) 12.6, .56, <.001
Age 54.3 (3.0) 56.4 (3.9) 57.2 (4.1) 4.71,.32, <.001
CD4+ cell count
Current 503.3 (273) 568.1 (279) 549.0 (272) .28, .09, >.10
Nadir
b 271.8 (70.0) 242.2 (134) 221.1 (126) .40, .11, >.10
HIV viral load
Current 2.12 (1.0) 2.01 (.92) 2.04 (.92) .08, .05, >.10
Peak
c 4.89 (.35) 5.22 (.41) 4.90 (.67) 1.36, .21, >.10
On HAART (percent (N)) 83 (19) 92 (12) 73 (35) 1.13, −.12, .29
d
aVisit with first confirmed HIV seropositivity. Includes both prevalent and incident cases (n=84)
bLowest measured CD4+ cell count prior to HAART (n=65)
cHighest HIV RNA prior to HAART (n=65)
d#
2, r, p
Brain Imaging and Behavior (2011) 5:77–85 81infection or seroconverted during that time period. The
group with the longest duration of infection will have had
the longest time without any treatment, will have had some
time with non-HAART monotherapy, and will have been
among the group that managed to survive the infection. The
group that became infected most recently had the opportu-
nity to receive HAART as the first line of therapy, and
likely had therapy initiated at an earlier point in the natural
history of the infection. This interpretation suggests that
earlier and more aggressive intervention may help protect
the brain from long-term effects of the virus (Marcondes et
al. 2009). However, a recent cross-sectional study (Cohen
et al. 2010) that found that nadir CD4+ cell counts and
duration of infection were related to cortical volume,
whereas caudate nucleus volumes were related to current
plasma viral load. When we examined the association
between the current HIV viral load and basal ganglia
volume among the men with measureable virus in plasma,
the correlation was modest, at best (r=−.21, p=.33, n=23).
The differences in the analysis technique, particularly the
method of the spatial normalization of the scans, may be
one source of difference between studies.
Alternatively, the effect of time may be the conse-
quence of a low grade, chronic process that alters brain
structure even when peripheral measures of viral load
and immunocompetence are within acceptable limits
(Chang et al. 2003;C h a n ge ta l .2002; Ernst and Chang
2004). There may be an ongoing process related to HIV
disease, which was not altered by the changing dynamics
of the infection, and which may not be reflected in the
clinical quiescent period (Cysique et al. 2005). Consistent
with this idea was the finding that the regions of the basal
ganglia that were significantly correlated with duration of
infection were similar in both location and extent of
contraction to those areas that were related to HIV disease
overall. The major differences between the maps were in
the local p-values, which were influenced by the sample
size used for the two analyses.
We favor the first of these hypotheses in part because
it is more parsimonious, but also because it seems to be
more in line with the accumulating data that suggest that
what we are observing is the damage done to the CNS
prior to the initiation of HAART. For example, data from
a study in China have found that while cognitive functions
Fig. 1 The regions of the CDTand PUTwhere the mean radial size of
these structures was lower in the HIV-infected versus the control
group. The images show the inferior surfaces of both the caudate and
putamen in radiological orientation (i.e., looking towards the reader);
the areas separated in the figure to ease viewing, and do not represent
the actual spatial contiguity of the regions. The top row of the figure
shows the areas of contraction as a function of serostatus (left) and
time since first seropositivity (right). The areas of red have no
significant contraction, and those with purple have ~15% contraction.
The bottom row of the figure shows the local significance values from
the test for group differences in the degree of atrophy for the CDT and
PUT. Areas of dark blue have no significant change (by permutations
testing) and those marked in white have highly significant effects
(P’s<.01 and smaller)
82 Brain Imaging and Behavior (2011) 5:77–85improve with anti-retroviral therapy, these patients did not
return to normal (Cysique et al. 2010). Distinguishing between
these two hypotheses is critical for understanding the effects
of HIV on the CNS, and for developing rational treatment
policies. However, this will require longitudinal data from
HIV-infected individuals with a range of time-since-infection,
and a substantial group with exposure only to HAART.
Several points should be considered when interpreting
these data. The MACS Cardiovascular substudy was
initiated in 2004 and included men age ≥40 years, with
no self-reported history of clinical heart disease or
cerebrovascular disease; all of the participants in this
MRI study were at least 50 years old. Thus, these are
individuals who, by and large, survived for 15–25 years
with the virus, without developing significant age- and
treatment-related comorbidities that are becoming in-
creasingly common as the epidemic ages. None of the
m e ni nt h es t u d ym e tc r i t e r i af o rH I V - A s s o c i a t e d
Dementia, although 9/84 (11%) performed in the mildly
impaired range (i.e., asymptomatic impairment or minor
neurocognitive disorder) (Antinori et al. 2007). Further-
more, we have noted previously (Becker et al. 2009), that
the overall health of the HIV-infected men in this study is
generally better than that of the seronegative control
participants. Consequently, the men with HIV disease likely
had fewer vascular risk factors for cognitive impairment and
brain atrophy due to aggressive use of statins and anti-
hypertensive medications, and they are also individuals who
may have a different physiological resistance relative to
individuals who succumbed to HIV. Finally, the HIV-
infected men who were enrolled in the MACS in 2001–2003
andwhowereonHAARTatthetimethattheyenrolledalso:a)
had to have had a known date of HAART initiation, b) could
not have had an AIDS diagnosis before (or coincident with)
the initiation of HAART, and c) had to have had HIV RNA
and CD4+ data within 4 months before HAART initiation.
This meansthat thosemen whodid not haveasgoodaccessto
care, or who were not as healthy were not included in this
recruitment wave.
These findings are consistent with our prior studies using a
different cohort of HIV-infected individuals who had poorer
health-related outcomes. For example, we found significant
bilateral brain atrophy that was correlated with cognitive
impairment and CD4+ cell counts (Chiang et al. 2007), while
others (Paul et al. 2008) report that the basal ganglia were
smaller, although not significantly, among HIV + individu-
als. However, the younger age of that sample (mean
~38 years) suggests a shorter duration of infection, which
may be linked to less volume loss. The findings of increased
brain region size (Castelo et al. 2007) are more difficult to
reconcile, and there may have been some differences in the
sampling frame relative to the present study that may have
accounted for the differences between the studies.
HIV viral proteins are neurotoxic, so the volumetric
differences found here may reflect neuronal loss, reduced
dendritic complexity, synaptic loss (Wiley et al. 1991),
and associated white matter degeneration. HAART med-
ications often fail to significantly penetrate the blood brain
barrier (Cysique et al. 2004), so brain atrophy may still
occur in patients treated with antiretroviral medication.
The MACS has previously shown that levels of viremia
and CD4+ cell count predict the onset of HIV-Associated
Dementia and neuropathy prior to the use of HAART
(Childs et al. 1999). The data that we present here suggest
that the overall duration of infection may be an important
predictor of the extent of CNS damage—even if viral load
and CD4+ cell counts are currently under control. Our
study participants who have been infected for more than
15 years would have suffered a progressive loss of gray
a n dw h i t em a t t e r ,a n ds p e c i f i cl o s si nt h eC D T( S t o u te ta l .
1998). With the advent of effective therapy, this loss may
have slowed, but was not arrested. The use of medications
with higher CNS penetrance would have offered greater,
but not complete protection, to the CNS (Marra et al. 2003;
Marra et al. 2009). Thus, we would expect that with earlier
and better control of viral replication, the CNS complications
of HIV disease, especially those related to CNS structure, will
be greatly attenuated.
While there are limitations to the sample of participants
usedinthisstudy,thereareimportantaspectsofthisgroupthat
render these data unique. Because of the extensive follow-up
in the MACS, as many as 25 years of data are available on the
participantsinthestudy.ViralloadandCD4+cellcountswere
measuredthroughoutthe historyoftheirinfection.Themenin
the study had no clinically manifest cardiovascular disease at
the time of their scan. While this biases the sample somewhat,
the volunteersinthisstudy provide a richsubstrate toevaluate
effectsofincident CVD on CNS structure and function in the
context of HIV disease.
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